title: Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
abstract: Gonadotropin-releasing hormone analog depots have been widely used for a variety of diseases including prostate cancer, breast cancer, endometriosis, uterine leiomyomas, and central precocious puberty. Most of the side/adverse effects of gonadotropin-releasing hormone analog depots, such as leuprorelin acetate depot, are related to hypotestosteronism in males. Anaphylaxis to gonadotropin-releasing hormone analog depot is extremely rare. We present the first case report of a Japanese man who developed anaphylaxis to leuprorelin acetate depot during the treatment of metastatic prostate cancer and recovered successfully by conservative treatment. A drug-lymphocyte stimulation test showed that not only leuprorelin acetate itself, but also its vehicle polylactic and glycolic acids, might be responsible for the anaphylaxis to leuprorelin acetate depot. Because anaphylaxis can be lethal, the present case suggests that one should bear in mind the possibility of anaphylaxis in all patients who receive gonadotropin-releasing hormone analog depot and monitor such patients carefully.
authors: Department of Urology, Jichi Medical University, Shimotsuke-city, Tochigi, Japan.
authors: Akira
authors: A
authors: Fujisaki
authors: Yoshimasa
authors: Y
authors: Kondo
authors: Kentaro
authors: K
authors: Goto
authors: Tatsuo
authors: T
authors: Morita
mesh_terms: D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced* / Q000188:drug therapy; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology; D017809:Fatal Outcome; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016729:Leuprolide / Q000009:adverse effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007166:Immunosuppressive Agents; D016729:Leuprolide